Sirio Pharma Hits Day Low of CNY 18.70 Amid Price Pressure

Sirio Pharma Co., Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 5.48% on March 23, 2026. The stock reached an intraday low of CNY 18.70, reflecting ongoing challenges in its market performance. Over the past week, Sirio Pharma has seen a decrease of 8.7%, while its performance over the last month has been even more pronounced, with a decline of 13.29%. Year-to-date, the stock has fallen by 27.34%, significantly underperforming the China Shanghai Composite, which has only dipped by 3.92% during the same period. Key financial metrics indicate that the company is facing pressure, with a return on equity of 11.84% and a price-to-book ratio of 2.09. Additionally, the company's debt-equity ratio stands at 0.29, suggesting a relatively stable capital structure. However, the stock's performance over the last five years has been particularly concerning, with a decline of 43.82%, highlighting a trend of underperformance relative to broader market indices.